RXPA 380 is a C-terminal specific angiotensin-converting enzyme (ACE) inhibitor with a Ki of 3 nM. RXPA 380 inhibits C-domain mutants of human recombinant ACE with an IC50 of 2.5 nM[1].
Tissue: peripheral blood; Tumor: leukemia, pre-B cell; Derived from a patient with acute lymphoblastic leukemia (ALL) in relapse. Karotype: (8;14) And (14;18) Translocations. EBNA negative.